EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Validation of a targeted metabolomics panel for improved second‐tier newborn screening

Justin Mak iD, Gang Peng, Anthony Le, Neeru Gandotra, Gregory M Enns, Curt Scharfe, Tina M Cowan

Journal of Inherited Metabolic Disease · 2023-03 · 46 (2) · 194-205

DOI: 10.1002/jimd.12591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 02.02.2023. Verfasst von Justin Mak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Biochemical Genetics Laboratory, Stanford Health Care, Stanford, California, USA. Hauptthemen laut MEDLINE: Neonatal Screening, Ornithine Carbamoyltransferase Deficiency Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Improved second‐tier assays are needed to reduce the number of false positives in newborn screening (NBS) for inherited metabolic disorders including those on the Recommended Uniform Screening Panel (RUSP). We developed an expanded metabolite panel for second‐tier testing of dried blood spot (DBS) samples from screen‐positive cases reported by the California NBS program, consisting of true‐ and false‐positives from four disorders: glutaric acidemia type I (GA1), methylmalonic acidemia (MMA), ornithine transcarbamylase deficiency (OTCD), and very long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD). This panel was assembled from known disease markers and new features discovered by untargeted metabolomics and applied to second‐tier analysis of single DBS punches using liquid chromatography–tandem mass spectrometry (LC–MS/MS) in a 3‐min run. Additionally, we trained a Random Forest (RF) machine learning classifier to improve separation of true‐ and false positive cases. Targeted metabolomic analysis of 121 analytes from DBS extracts in combination with RF classification at a sensitivity of 100% reduced false positives for GA1 by 83%, MMA by 84%, OTCD by 100%, and VLCADD by 51%. This performance was driven by a combination of known disease markers (3‐hydroxyglutaric acid, methylmalonic acid, citrulline, and C14:1), other amino acids and acylcarnitines, and novel metabolites identified to be isobaric to several long‐chain acylcarnitine and hydroxy‐acylcarnitine species. These findings establish the effectiveness of this second‐tier test to improve screening for these four conditions and demonstrate the utility of supervised machine learning in reducing false‐positives for conditions lacking clearly discriminating markers, with future studies aimed at optimizing and expanding the panel to additional disease targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal ScreeningOrnithine Carbamoyltransferase Deficiency DiseaseTandem Mass SpectrometryChromatography, LiquidInfant, NewbornHumansCarnitineAmino Acid Metabolism, Inborn ErrorsBrain Diseases, MetabolicGlutaryl-CoA DehydrogenaseLipid Metabolism, Inborn ErrorsMuscular DiseasesMitochondrial DiseasesCongenital Bone Marrow Failure Syndromes

Stichwörter der Autor:innen

inborn metabolic disordersmachine learningmetabolomicsnewborn screeningsecond-tier testingsupervised machine learningtandem mass spectrometry

Substanzen

acylcarnitineCarnitineGlutaryl-CoA Dehydrogenase

Autor:innen und Institutionen

  • Clinical Biochemical Genetics Laboratory, Stanford Health Care, Stanford, California, USA.
  • Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.

ORCID-Profile: Justin Mak

Förderung

  • NICHD NIH HHS
  • National Institute of Child Health and Human Development

Zitieren

APA

Mak, J., Peng, G., Le, A., Gandotra, N., Enns, G. M., Scharfe, C., & Cowan, T. M. (2023). Validation of a targeted metabolomics panel for improved second‐tier newborn screening. Journal of Inherited Metabolic Disease, 46(2), 194-205. https://doi.org/10.1002/jimd.12591

Vancouver

Mak J, Peng G, Le A, Gandotra N, Enns GM, Scharfe C, et al. Validation of a targeted metabolomics panel for improved second‐tier newborn screening. Journal of Inherited Metabolic Disease. 2023;46(2):194-205. doi:10.1002/jimd.12591

BibTeX
@article{Mak2023,
  author = {Mak, Justin and Peng, Gang and Le, Anthony and Gandotra, Neeru and Enns, Gregory M and Scharfe, Curt and Cowan, Tina M},
  title = {Validation of a targeted metabolomics panel for improved second‐tier newborn screening},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2023},
  volume = {46},
  number = {2},
  pages = {194--205},
  doi = {10.1002/jimd.12591}
}
Kostenlos starten →